Clinical Research Directory
Browse clinical research sites, groups, and studies.
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
Sponsor: Heinrich-Heine University, Duesseldorf
Summary
PRIMETEST II is an interventional study involving low-volume metastatic seminoma. It explores a novel approach using robot-assisted primary retroperitoneal lymph node dissection, aiming to reduce long-term side effects and improve quality of life. By identifying factors predicting cancer recurrence, the study hopes to tailor treatments for better outcomes. The approach could potentially spare patients from chemotherapy induced long-term side effects while maintaining excellent survival rates, presenting a promising shift in testicular cancer care for this specific patient group.
Official title: PRIMETEST II - Phase II Trial to Prospectively Test New Predictors for Recurrence in Patients With Clinical Stage II A/B Seminoma Treated With RA-RPLND
Key Details
Gender
MALE
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-08-28
Completion Date
2029-08-31
Last Updated
2025-09-15
Healthy Volunteers
No
Conditions
Interventions
Robot-assisted retroperitoneal lymph node dissection
Robot-assisted, if possibe ipsilateral nerve-sparing, retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field ("template")
Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin
The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
Locations (1)
University Hospital of Duesseldorf
Düsseldorf, Germany